Skip navigation
alt

Signatera Looks Deeper 

Personalized tumor-informed test for actionable intelligence

Explore the three new studies recently presented at the 2020 American Society of Clinical Oncology (ASCO) virtual conference and access additional content below. The oral presentation and 2 posters highlight the unique applications of Signatera to detect recurrence using circulating-tumor DNA (ctDNA).

Ma

On-Demand ASCO Presentations

ORAL PRESENTATION
POSTER PRESENTATION
  • Tumor informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced stage colorectal cancer (CRC MRD Consortia)

    ABSTRACT / POSTER: 4108 • 100
    Pashtoon Kasi, MD, MS
    Assistant Professor, College of Medicine and Oncology, University of Iowa
  • Characterization of clonal hematopoiesis of indeterminate potential (CHIP) mutations from germline whole exome sequencing Data

    ABSTRACT / POSTER: 1525 • 17
    Hsin Ta Wu, PhD
    Manager, Bioinformatics (Oncology & Algorithm Development), Natera

Dive Deeper

For Physicians

What are the Potential Clinical Applications of Signatera?
Video
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer
Article
Seeing beyond the limit: Detect residual disease and assess treatment response
Whitepaper

FOR CLINICAL RESEARCHERS

How can Signatera be Incorporated in Clinical Trials?
VIDEO
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
Article
Detecting molecular residual disease with Signatera
Whitepaper

Learn More

Presentations will be available for on-demand viewing and download. Sign up here to receive access.